# EDGAR Filing Document

**Accession Number:** 0001484565
**File Stem:** 0001193125-26-212205
**Filing Date:** 2026-5
**Character Count:** 131186
**Document Hash:** afb012fff1be61671250a391306afa45
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212205.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212205

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 70

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SOLENO THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001484565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770523891
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36593
- **FILM NUMBER:** 26954404

**BUSINESS ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-213-8444

**MAIL ADDRESS:**
- **STREET 1:** 100 MARINE PARKWAY, SUITE 400
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Capnia, Inc.
- **DATE OF NAME CHANGE:** 20100219

?xml version='1.0' encoding='ASCII'? 10-Q

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

------

**FORM** 10-Q

------

**(Mark One)** 

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the quarterly period ended** **March 31,** 2026

**or** 

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**For the transition period from to** 

**Commission File Number:** 001-36593

------

Soleno Therapeutics, Inc.

**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| Delaware | 77-0523891 |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

100 Marine Parkway**,** Suite 400

Redwood City**,** California

**(Address of principal executive offices)** 

94065

**(Zip Code)** 

**(**650**)** 213-8444

**(Registrant's telephone number, including area code)** 

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>Securities registered pursuant to Section 12(b) of the Act: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>Securities registered pursuant to Section 12(b) of the Act: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br>Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | SLNO | NASDAQ |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 30, 2026, there were 52,120,147 shares of the registrant's Common Stock, par value $0.001 per share, outstanding.

------

**SOLENO THERAPEUTICS, INC.** 

**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
|  | **Page** |
| &nbsp;&nbsp;&nbsp;&nbsp;[**<u>PART I—FINANCIAL INFORMATION</u>**](#part_ifinancial_information) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 1. Financial Statements</u>](#item1_financial_statements) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Balance Sheets (unaudited)</u>](#condensed_consolidated_balance_sheets) | 3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited)</u>](#cndnsd_cnsldtd_stmnt_oprns_comprehensive) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Stockholders' Equity (unaudited)</u>](#condensed_consolidated_statements_stockh) | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Condensed Consolidated Statements of Cash Flows (unaudited)</u>](#cndnsd_cnsolidated_statements_cash_flows) | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>](#notes_consolidated_financial_statements) | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 23 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3_quantitative_and_qualitative) | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 4. Controls and Procedures</u>](#controls_and_procedures) | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;[**<u>PART II—OTHER INFORMATION</u>**](#part_ii_other_information) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 1. Legal Proceedings</u>](#item_1_legal_proceedings) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 1A. Risk Factors</u>](#item_1a_risk_factors) | 28 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 3. Defaults Upon Senior Securities</u>](#item_3_defaults_upon_senior_securities) | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 4. Mine Safety Disclosures</u>](#item_4_mine_safety_disclosures) | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 5. Other Information</u>](#item_5_or_information) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Item 6. Exhibits</u>](#item_6_exhibits) | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;[**<u>EXHIBIT INDEX</u>**](#exhibit_index) | 31 |
| &nbsp;&nbsp;&nbsp;&nbsp;[**<u>SIGNATURES</u>**](#signatures) | 31 |

---

------

**PART I—FINANCIAL INFORMATION**

**Item 1. Financial Statements** 

**Soleno Therapeutics, Inc.** 

**Condensed Consolidated Balance Sheets** 

*(in thousands, except share and per share data)* 

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | **(unaudited)** |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $133026 | $70106 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketable securities | 122573 | 235366 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 47139 | 28208 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory, net | 17308 | 15024 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 6330 | 7110 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 326376 | 355814 |
| Long-term assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 202 | 185 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets | 3891 | 2191 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 4374 | 4861 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term marketable securities | 273382 | 200616 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 163 | 163 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $608388 | $563830 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $12386 | $12435 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 5723 | 9677 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | 1163 | 726 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contingent liability for Essentialis purchase price | 13846 | 20327 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current liabilities | 24931 | 18198 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 58049 | 61363 |
| Long-term liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term debt, net | 49871 | 49863 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term lease liabilities | 3243 | 1964 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | 1425 | 525 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 112588 | 113715 |
| Commitments and contingencies (Note 6) |  |  |
| Stockholders' equity |  |  |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding | - | - |
| Common stock, $0.001 par value, 100,000,000 shares authorized,<br>51,718,149 and 52,286,881 shares issued and outstanding at<br> March 31, 2026 and December 31, 2025, respectively | 52 | 52 |
| Additional paid-in-capital | 897578 | 881018 |
| Accumulated other comprehensive income (loss) | (1838) | 415 |
| Accumulated deficit | (399992) | (431370) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 495800 | 450115 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $608388 | $563830 |

---

*See accompanying notes to condensed consolidated financial statements* 

------

**Soleno Therapeutics, Inc.**

**Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)**

**(unaudited)** 

*(in thousands, except share and per share data)* 

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Product revenue, net | $94603 | $— |
| Operating expenses |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 1198 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 11274 | 13517 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 50369 | 29259 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 484 | 2967 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 63325 | 45743 |
| Operating income (loss) | 31278 | (45743) |
| Other income (expense), net |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 4927 | 3331 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1292) | (1361) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense), net | 3635 | 1970 |
| Income (loss) before provision for income taxes | 34913 | (43773) |
| Provision for income taxes | 3535 |  |
| Net income (loss) | $31378 | $(43773) |
| Other comprehensive income (loss) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net unrealized loss on marketable securities | (2225) | (139) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | (28) | 4 |
| Total comprehensive income (loss) | $29125 | $(43908) |
| Net income (loss) | 31378 | (43773) |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Undistributed earnings attributable to participating securities | (1) |  |
| Net income (loss) attributable to common stockholders - basic and diluted | $31377 | $(43773) |
| Net income (loss) per share - basic | $0.60 | $(0.95) |
| Net income (loss) per share - diluted | $0.59 | $(0.95) |
| Weighted-average common shares outstanding - basic | 52091047 | 46178793 |
| Weighted-average common shares outstanding - diluted | 53066971 | 46178793 |

---

*See accompanying notes to condensed consolidated financial statements* 

------

**Soleno Therapeutics, Inc.** 

**Condensed Consolidated Statements of Stockholders' Equity**

**For the Three Months Ended March 31, 2026 and 2025** 

**(unaudited)** 

*(in thousands, except share data)* 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  | **Accumulated** |  |  |
|  |  |  | **Additional** | **Other** |  | **Total** |
|  | **Common Stock** | **Common Stock** | **Paid-In** | **Comprehensive** | **Accumulated** | **Stockholders'** |
|  | **Shares** | **Amount** | **Capital** | **Income** | **Deficit** | **Equity** |
| Balances at January 1, 2026 | 52286881 | $52 | $881018 | $415 | $(431370) | $450115 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | - | - | 16509 | - | - | 16509 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (662497) | - | - | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units | 93794 | - | 52 | - | - | 52 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholding payments for net share-settled equity awards | (29) | - | (1) | - | - | (1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net unrealized loss on marketable securities | - | - | - | (2225) | - | (2225) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | - | - | - | (28) | - | (28) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | - | - | - | - | 31378 | 31378 |
| Balances at March 31, 2026 | 51718149 | $52 | $897578 | $(1838) | $(399992) | $495800 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  | **Accumulated** |  |  |
|  |  |  | **Additional** | **Other** |  | **Total** |
|  | **Common Stock** | **Common Stock** | **Paid-In** | **Comprehensive** | **Accumulated** | **Stockholders'** |
|  | **Shares** | **Amount** | **Capital** | **Income** | **Deficit** | **Equity** |
| Balances at January 1, 2025 | 45703811 | $46 | $696966 | $361 | $(452260) | $245113 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | - | - | 14679 | - | - | 14679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units | 943980 | 1 | 13365 | - | - | 13366 |
| &nbsp;&nbsp;&nbsp;&nbsp;Exercise of common stock warrants | 1879678 | 2 | 3009 | - | - | 3011 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net unrealized loss on marketable securities | - | - | - | (139) | - | (139) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | - | - | - | 4 | - | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss | - | - | - | - | (43773) | (43773) |
| Balances at March 31, 2025 | 48527469 | $49 | $728019 | $226 | $(496033) | $232261 |

---

*See accompanying notes to condensed consolidated financial statements* 

------

**Soleno Therapeutics, Inc.** 

**Condensed Consolidated Statements of Cash Flows** 

**(unaudited)** 

*(in thousands)* 

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Cash flows from operating activities:** |  |  |
| Net income (loss) | $31378 | $(43773) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 514 | 504 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion of premium/discount on marketable securities | (221) | (980) |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease expense | 149 | 195 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 8 | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 16056 | 14679 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 484 | 2967 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-cash reconciling items | (28) | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (18931) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (1831) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses, other current assets and other assets | 780 | (3416) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (2970) | (3336) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | (3954) | (499) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (133) | (40) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Essentialis acquisition milestone payments | (2954) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 7633 | 935 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) operating activities** | 25980 | (32752) |
| **Cash flows from investing activities:** |  |  |
| Purchases of property and equipment | (40) | (5) |
| Purchases of marketable securities | (101268) | (45358) |
| Maturities of marketable securities | 139291 | 68300 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by investing activities** | 37983 | 22937 |
| **Cash flows from financing activities:** |  |  |
| Payment for repurchase of common stock | (4) | - |
| Payment of debt issuance costs | - | (62) |
| Proceeds from exercise of common stock warrants | - | 3011 |
| Proceeds from exercise of stock options | 52 | 269 |
| Tax withholding payments for net share-settled equity awards | (1) | - |
| Essentialis acquisition milestone payments | (1090) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by (used in) financing activities** | (1043) | 3218 |
| Net increase (decrease) in cash and cash equivalents | 62920 | (6597) |
| Cash and cash equivalents, beginning of period | 70106 | 87928 |
| **Cash and cash equivalents, end of period** | $133026 | $81331 |
| **Supplemental disclosure of non-cash operating and financing information** |  |  |
| Cash paid for interest | $1155 | $805 |
| Operating lease right-of-use assets obtained in exchange for operating lease obligations | $1849 | $- |
| Purchases of property and equipment included in accounts payable | $4 | $- |

---

*See accompanying notes to condensed consolidated financial statements.* 

------

**Soleno Therapeutics, Inc.** 

**March 31, 2026**

**Notes to Condensed Consolidated Financial Statements** 

**(unaudited)** 

**Note 1. Overview** 

Soleno Therapeutics, Inc. (the Company or Soleno) is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. The Company is incorporated in the State of Delaware and is headquartered in Redwood City, California.

On March 26, 2025, the Company announced that its lead product candidate, VYKAT<sup>TM</sup> XR (diazoxide choline) extended-release tablets, formerly known as DCCR, had been approved by the U.S. Food and Drug Administration (FDA). VYKAT XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). On April 14, 2025, the Company announced that prescriptions of VYKAT XR had been delivered to the first individuals living with PWS who had been prescribed the medication and began recognizing revenue from the sales of VYKAT XR during the three months ended June 30, 2025. On April 6, 2026, the Company announced that it had entered into an Agreement and Plan of Merger (the Merger Agreement) with Neurocrine Biosciences, Inc. (Neurocrine) and Sigma Merger Sub, Inc. (Merger Sub) on April 5, 2026, pursuant to which Neurocrine, through Merger Sub, agreed to commence a cash tender offer (the Offer) to purchase all of the issued and outstanding shares of the common stock of the Company at a price per share of $53.00 per share. The Offer commenced on April 20, 2026 and is expected to close during the three months ending June 30, 2026, pursuant to the terms of the Merger Agreement, with the result being the Company becoming a wholly-owned subsidiary of Neurocrine.

**Note 2. Liquidity**

The Company generated $26.0 million of net cash from its operating activities, had a net income of $31.4 million during the three months ended March 31, 2026 and had an accumulated deficit of $400.0 million at March 31, 2026, as a result of losses incurred prior to 2025. The Company had $133.0 million of cash and cash equivalents and $396.0 million of marketable securities as of March 31, 2026. With FDA approval of VYKAT XR and first prescriptions being delivered in April 2025, the Company began recognizing revenue and became profitable during 2025. The Company's ability to sustain operating profitability is dependent upon continued successful commercialization of VYKAT XR.

As of March 31, 2026, the Company had $50.0 million outstanding under the loan and security agreement with Oxford Financing LLC and its affiliates (collectively, Oxford) entered into in December 2024. Under the terms of the loan agreement with Oxford, following FDA approval of VYKAT XR, an additional $50 million became available through September 30, 2025, but was not drawn down. Following the amendment of the Company's loan and security agreement in November 2025, the final three tranches of aggregate of $100 million may be made available upon mutual consent with Oxford. As a result of a milestone achieved in 2025, the loan carries an interest-only period of 60 months and a total term of 72 months. The term loan accrues interest at a floating rate equal to, subject to certain conditions, (a) 1-month term SOFR plus (b) 5.50%.

In addition to the Oxford loan and security agreement, the Company has historically financed its operations through issuance of equity securities. In July 2025, the Company closed an underwritten public offering of 2,705,882 shares of its common stock at an offering price of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $230.0 million, before deducting the underwriter discount and other offering expenses, totaling approximately $14.3 million.

The Company expects that its current cash, cash equivalents and marketable securities balances and cash flows from operations will be sufficient to enable the Company to meet its obligations for at least the next twelve months from the date of this filing.

**Note 3. Basis of Presentation and Summary of Significant Accounting Policies** 

***Significant Accounting Policies*** 

There have been no material changes to the significant accounting policies during the three months ended March 31, 2026 as compared to the significant accounting policies described in Note 3 of the "Notes to Consolidated Financial Statements" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

***Basis of Presentation*** 

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP,

------

the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2026. For further information, refer to the financial statements and footnotes included in the Company's annual financial statements for the fiscal year ended December 31, 2025, which are included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2026.

***Use of Estimates*** 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of expenses in the financial statements and accompanying notes. Actual results could differ from those estimates. Significant estimates made by management include valuation of marketable securities, stock-based compensation, valuation of contingent liabilities for the purchase price of assets obtained through acquisition, provisions for sales rebates, returns and other incentives, valuation of financial instruments, and income taxes.

***Accounts Receivable, net***

Accounts receivable, net consists of amounts due from customers, net of customer allowances for cash discounts and any estimated expected credit losses. The Company's measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. To date, the Company has not experienced any credit losses. The Company's contract with its customer has customary payment terms that require payment within 45 days. The Company analyzes amounts that are past due for collectability, and periodically evaluates the creditworthiness of its customer. Based on its assessment, as of March 31, 2026, the Company determined that an allowance for credit loss was not required.

***Concentration of Major Customers and Off-Balance Sheet Risk***

The Company contracts with one customer, its specialty pharmacy, to market and distribute VYKAT XR to patients in the United States. As of March 31, 2026, its accounts receivable, net are solely from sales of VYKAT XR, and are from this sole customer.

The Company's dependency on one customer exposes it to several risks, including the potential for disruptions in its distribution network, changes in this customer's business strategies, or financial difficulties faced by this customer. Any significant disruption or change in the Company's relationship with this customer could materially and adversely affect its ability to effectively reach other potential end users and maintain its market position.

While the Company believes its relationship with this customer is strong and mutually beneficial, there can be no assurance that it will be able to maintain this relationship or that it will be able to replace this specialty pharmacy with alternative specialty pharmacies, if necessary.

The Company relies on sole source suppliers and third-party manufacturers to supply raw materials and manufacture its product. The inability of these suppliers or manufacturers to fulfill supply requirements of the Company could materially impact future operating results. A change in the relationship with these suppliers or manufacturers, or an adverse change in their business, could materially impact future operating results.

***Revenue Recognition***

The Company recognizes revenue in accordance with ASC Topic 606, *Revenue from Contracts with Customers*, or ASC 606. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services.

*Product Revenue, net*

The Company currently sells its product primarily to one customer, a specialty pharmacy. The product is distributed through a third-party logistics distribution agent (3PL) that does not take title to the product. In the Company's agreement with the 3PL, the Company acts as principal because it retains control of the product. Once the product is delivered to the Company's specialty pharmacy, the specialty pharmacy takes title to the product. The specialty pharmacy then distributes the product to patients. The Company offers returns of product sold to the customer on a limited basis; however, no material returns have been recognized to date.

Revenue from product sales is recognized when the customer obtains control of the Company's product, which occurs at the point in time that there is a transfer of title to the customer. The Company has no other performance obligations besides the sale of product, and because the Company's payment terms are 45 days or less, the Company concluded there is not a significant financing component. The Company classifies payments to its customers or other parties in the distribution channel for services that are distinct

------

and priced at fair value as selling, general and administrative expenses in its condensed consolidated statements of operations and comprehensive income (loss). Otherwise, payments to a customer or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. The Company expenses incremental costs of obtaining a contract as and when incurred since the expected amortization period of the asset that the Company would have recognized is one year or less.

*Reserves for Variable Consideration*

Revenues from product sales are recorded at the net sales price, or the transaction price, which includes estimates of variable consideration for which reserves are established and which result from rebates, discounts, returns, and co-pay assistance that are offered within the contract between the Company and its customer relating to the sale of VYKAT XR. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than the customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is considered probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from the Company's estimates, it will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

The following are the components of variable consideration related to product revenue:

*Government rebates:* The Company is subject to discount obligations under several government programs, including Medicaid programs, Medicare and TRICARE in the United States. The Company estimates these rebates based upon a range of possible outcomes that are weighted for the estimated payer mix. These reserves are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability that is included in other current liabilities on the Company's condensed consolidated balance sheets. On a quarterly basis, the Company updates its estimates and records any adjustments in the period that it identifies the adjustments.

*Trade discounts and allowances:* The Company provides discounts on VYKAT XR sales to its customer for prompt payment. This discount is recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives and pays for various distribution services from its customer in the distribution channel.

*Product returns:* The Company's customer has limited return rights related to unexpected instances in which the product is found to be damaged or defective. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of revenue and a refund liability in the period in which the related product revenue is recognized. Based on the distribution model for VYKAT XR, the Company believes there will be minimal returns as such returns have not been material to date.

*Other incentives:* Other incentives include co-payment assistance the Company provides to patients with commercial insurance that have coverage and reside in states that allow co-payment assistance. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue. The estimate is recorded as a reduction of revenue in the same period the related revenue is recognized.

Provisions for trade discounts and allowances are recorded as reductions to accounts receivable, and returns, government rebates, and other incentives are recorded as a component of accrued expenses.

The table below summarizes balances and activity in each of the product revenue allowance and reserve categories as follows (in thousands):

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Rebates** | **Discounts and Chargebacks** | **Copay Assistance and Returns** | **Total** |
| Balance as of December 31, 2025 | $13685 | $723 | $347 | $14755 |
| &nbsp;&nbsp;Provisions | 12243 | 2743 | 913 | 15899 |
| &nbsp;&nbsp;Credits/payments | (10239) | (2257) | (904) | (13400) |
| Balance as of March 31, 2026 | $15689 | $1209 | $356 | $17254 |

---

***Inventory***

The Company capitalizes inventory costs associated with products when future economic benefit is expected to be realized. These costs consist of raw materials, manufacturing-related costs, personnel costs including stock-based compensation, facility costs, and other indirect overhead costs. Prior to receiving FDA approval for VYKAT XR in March 2025, the Company expensed costs related to inventory for clinical and pre-commercial purposes directly to research and development expense. Following the FDA's approval of VYKAT XR, the Company began capitalizing inventory related to commercialized products held for sale, in-process of production for sale, and raw materials to be used in the manufacturing of inventory.

The Company values inventory at the lower of cost or estimated net realizable value. The Company determines the cost of inventory, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis. Raw materials and work in process includes all inventory costs prior to packaging and labeling, including raw materials, active pharmaceutical ingredient, and drug product. Finished goods include packaged and labeled products. Raw materials and work in process that may be used for either research and development or commercial sale are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is intended to be used for research and development, it is expensed as research and development once that determination is made. On a quarterly basis, the Company analyzes its inventory levels for excess quantities and obsolescence (expiration), taking into account factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf life.

***Cost of Goods Sold***

Cost of goods sold consists of manufacturing costs, transportation and freight, amortization of capitalized intangibles, royalty payments and indirect overhead costs associated with the manufacturing and distribution of VYKAT XR. Cost of goods sold may also include periodic costs related to certain manufacturing services and inventory adjustment charges. Finally, cost of goods sold may also include costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances.

***Recent Accounting Pronouncements*** 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that are adopted by the Company as of the specified effective date.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. Early adoption is permitted. A public entity should apply the amendments in ASU 2023-09 prospectively to all annual periods beginning after December 15, 2024. The Company adopted this standard effective January 1, 2025 using a retrospective approach.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expense,* which requires the disclosure of additional information related to certain costs and expenses, including amounts of inventory purchases, employee compensation, and depreciation and amortization included in each income statement line item. The guidance also requires disclosure of the total amount of selling expenses and the Company's definition of selling expenses. The guidance is effective for the Company for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. The Company is currently assessing the impacts of the new guidance on its financial statement disclosures.

In July 2025, the FASB issued ASU 2025-05, *Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets*, which introduces a practical expedient permitting all entities to assume that current conditions as of the balance sheet date will remain unchanged for the life of the asset when estimating expected credit losses under ASC 606. For entities other than public business entities, the ASU also allows an accounting policy election to consider cash collections received after the balance-sheet date in their estimates. An entity that makes this election must disclose the date through which subsequent collections are evaluated. The ASU is effective for annual reporting periods beginning after December 15, 2025,

------

including interim periods within those years, with early adoption permitted. The Company adopted this standard effective January 1, 2026 using a prospective approach, and it has no impact on its disclosures and does not impact the results of operations or financial condition.

Other accounting standards that have been issued or proposed by FASB or other standards-setting bodies that do not require adoption until a future date are not currently expected to have a material impact on the Company's financial statements upon adoption.

**Note 4. Fair Value of Financial Instruments** 

The carrying value of the Company's cash, cash equivalents, accounts receivable and accounts payable, approximate fair value due to the short-term nature of these items.

Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level I — Unadjusted quoted prices in active markets for identical assets or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level II — Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Level III — Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.

The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The fair value of marketable securities, which are Level 2 financial instruments, is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers. Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at March 31, 2026 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** |
|  | **Amortized Cost** | **Unrealized Gains** | **Unrealized Losses** | **Estimated Fair Value** |
| U.S. Treasury securities | $221241 | $31 | $(879) | $220393 |
| Other government agency securities | 23226 | - | (85) | 23141 |
| Corporate debt securities and commercial paper | 153314 | 7 | (900) | 152421 |
| Total | $397781 | $38 | $(1864) | $395955 |

---

------

The following table sets forth the Company's financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements at March 31, 2026** | **Fair Value Measurements at March 31, 2026** | **Fair Value Measurements at March 31, 2026** | **Fair Value Measurements at March 31, 2026** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets** |  |  |  |  |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;Money market funds | $132632 | $132632 | $— | $— |
| &nbsp;&nbsp;Total cash equivalents | $132632 | $132632 | $— | $— |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;U.S. treasury securities | $220393 | $— | $220393 | $— |
| &nbsp;&nbsp;Other government agency securities | 23141 |  | 23141 |  |
| &nbsp;&nbsp;Corporate debt securities and commercial paper | 152421 |  | 152421 |  |
| &nbsp;&nbsp;Total marketable securities | 395955 |  | 395955 |  |
| Total assets | $528587 | $132632 | $395955 | $— |
| **Liabilities** |  |  |  |  |
| Essentialis purchase price contingency liability | $13846 | $— | $— | $13846 |
| Total liabilities | $13846 | $— | $— | $13846 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Fair Value Measurements at December 31, 2025** | **Fair Value Measurements at December 31, 2025** | **Fair Value Measurements at December 31, 2025** | **Fair Value Measurements at December 31, 2025** |
|  | **Total** | **Level 1** | **Level 2** | **Level 3** |
| **Assets** |  |  |  |  |
| Cash equivalents: |  |  |  |  |
| &nbsp;&nbsp;Money market funds | $63613 | $63613 | $— | $— |
| &nbsp;&nbsp;Total cash equivalents | $63613 | $63613 | $— | $— |
| Marketable securities: |  |  |  |  |
| &nbsp;&nbsp;U.S. treasury securities | $274832 | $— | $274832 | $— |
| &nbsp;&nbsp;Other government agency securities | 23216 |  | $23216 |  |
| &nbsp;&nbsp;Corporate debt securities and commercial paper | 137934 |  | 137934 |  |
| &nbsp;&nbsp;Total marketable securities | 435982 |  | 435982 |  |
| Total assets | $499595 | $63613 | $435982 | $— |
| **Liabilities** |  |  |  |  |
| Essentialis purchase price contingency liability | $20327 | $— | $— | $20327 |
| Total liabilities | $20327 | $— | $— | $20327 |

---

Based on the terms of the Company's completed merger with Essentialis on March 7, 2017, the Company was obligated to make cash earnout payments of up to a maximum of $20.9 million to the former Essentialis stockholders. The fair value of the Essentialis purchase price contingent liability is estimated using scenario-based methods based upon the Company's analysis of the likelihood of obtaining specified approvals from the U.S. Food and Drug Administration (FDA) as well as achieving two commercial sales milestones of $100 million and $200 million in cumulative revenue. The Level 3 estimates are based, in part, on subjective assumptions. The first commercial milestone of $100 million in cumulative revenue was met during the fourth quarter 2025, and earnout payments of approximately $4.0 million were paid during the three months ended March 31, 2026. The remainder of the first milestone payments of $2.9 million are in accounts payable as of March 31, 2026 awaiting settlement. We achieved the second and final commercial milestone of $200 million in cumulative revenue in the three months ended March 31, 2026.

The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers between levels within the hierarchy during the periods presented.

------

The following table sets forth a summary of the changes in the fair value of the Company's Level 3 liabilities for the three months ended March 31, 2026 and 2025 (in thousands):

---

| | |
|:---|:---|
|  | **Purchase Price** |
|  | **Contingent<br>Liability** |
| Balance at January 1, 2026 | $20327 |
| Contingent consideration milestone payments | (4044) |
| Contingent consideration milestone liability in accounts payable | (2921) |
| Change in value of contingent liability | 484 |
| Balance at March 31, 2026 | $13846 |
|  | **Purchase Price** |
|  | **Contingent<br>Liability** |
| Balance at January 1, 2025 | $14791 |
| Change in value of contingent liability | 2967 |
| Balance at March 31, 2025 | $17758 |

---

**Note 5. Balance Sheet Components**

Inventory consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Raw materials | $4771 | $6449 |
| Work in process | 5566 | 2710 |
| Finished goods | 7220 | 6022 |
| Less: Reserve for excess and obsolete inventory | (249) | (157) |
| Total inventory, net | $17308 | $15024 |

---

Other current liabilities consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31,<br>2026** | **December 31,<br>2025** |
| Product revenue reserve for rebates, returns, and other incentives | $16045 | $14031 |
| Accrued consulting and professional fees | 3905 | 1902 |
| Accrued research and development costs | 916 | 679 |
| Accrued income tax payable | 2770 | - |
| Accrued clinical trial site costs | 700 | 1130 |
| Accrued interest payable | 395 | 403 |
| Other | 200 | 53 |
| Total other current liabilities | $24931 | $18198 |

---

**Note 6. Commitments and Contingencies** 

***Facility Leases*** 

On June 13, 2024, the Company entered into an office lease in Redwood City, California for its headquarters facility. The lease provides office space of approximately 18,026 square feet and for base monthly rent payments beginning at $57,400 that increase annually by approximately 3.0% over the term of five years from the date of occupancy. In addition to base rent, the Company has agreed to reimburse the landlord for certain operating expenses under the terms of the lease. The lease commencement date was September 1, 2024 when the premises became available for occupancy. The Company's operating lease for its predecessor headquarters facility office space in Redwood City, California began on June 1, 2023 and expired in May 2025.

------

On November 25, 2025, the Company executed an amendment to its office lease in Redwood City, California for additional office space for its headquarters facility. The amendment provides additional office space of approximately 17,779 square feet and for base monthly rent payments beginning at $32,747 that increase annually to $79,650 in the final year of the lease in 2029. In addition to base rent, the Company has agreed to reimburse the landlord for certain operating expenses under the terms of the lease. The amended lease commencement date was March 10, 2026 when the premises became available for occupancy and the related operating lease ROU assets and liabilities were recorded in the Company's condensed consolidated balance sheet as of March 31, 2026.

The Company's operating lease right-of-use (ROU) assets, current operating lease liabilities and long-term operating lease liabilities each appear as a separate line within the Company's condensed consolidated balance sheets. In September 2024, the Company recorded an increase to its ROU assets by $2.8 million and an increase to its lease liability of $2.8 million as a result of the June 2024 office lease. In March 2026, the Company recorded an increase to its ROU assets by $1.8 million and an increase to its lease liability of $1.8 million as a result of the November 2025 office lease. As of March 31, 2026 and December 31, 2025, the Company's short-term lease liabilities were equal to $1.2 million and $0.7 million, respectively, and the long-term operating lease liabilities were equal to $3.2 million and $2.0 million, respectively.

The weighted average discount rate related to the Company's lease liabilities was 9.6% as of March 31, 2026 over a remaining term of 3.4 years, and 8.5% as of December 31, 2025 over a remaining term of 3.7 years. The discount rate was determined based on estimates of the Company's incremental borrowing rate, as the discount rate implicit in the lease cannot be readily determined.

The components of lease expense were as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Operating lease cost: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease cost | $216 | $258 |
| &nbsp;&nbsp;&nbsp;&nbsp;Variable lease cost | - | 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;Short-term lease cost | 75 | 14 |
| Total operating lease cost | $291 | $276 |

---

Supplemental cash flow information related to leases was as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| Operating cash flows from operating leases | $201 | $103 |

---

The following is a schedule by year of future maturities of the Company's operating lease liabilities as of March 31, 2026 (in thousands):

---

| | |
|:---|:---|
| 2026 (remainder of the year) | $810 |
| 2027 | 1367 |
| 2028 | 1777 |
| 2029 | 1302 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease payments | 5256 |
| Less interest | (850) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $4406 |

---

***Other Commitments***

The Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services and supplies, and vendors for preclinical studies as well as other services and products for operating purposes, which are generally cancelable upon written notice. As of March 31, 2026, the Company's non-cancelable other commitments were $16.2 million in the aggregate.

------

***Contingencies*** 

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated.

**Note 7. Long-term Debt**

On December 17, 2024, the Company entered into a loan and security agreement for up to $200 million with Oxford. The loan is collateralized by substantially all of the Company's assets, including its intellectual property, subject to certain limitations.

As of March 31, 2026, the Company had $50.0 million outstanding under the loan and security agreement with Oxford. Under the terms of the loan agreement with Oxford, following FDA approval of VYKAT XR, an additional $50 million became available through September 30, 2025, but was not drawn down. Following the amendment of the loan and security agreement in November 2025, the final three tranches of an aggregate of $100 million may be made available upon mutual consent with Oxford. As a result of a milestone achieved in 2025, the loan carries an interest-only period of 60 months and a total term of 72 months. The term loan accrues interest, payable monthly, at a floating rate equal to, subject to certain conditions, (a) 1-month term SOFR plus (b) 5.50%. As a result of a milestone achieved in 2025, the term loan will begin to amortize in equal monthly installments beginning on February 1, 2030, through the maturity date of December 1, 2030. As a result of a milestone achieved in 2025, the final principal payment will include a fee of 6.5% of the total principal borrowed. The $3.3 million final interest payment related to the $50 million borrowed as of March 31, 2026 is accrued over the term of loan as long-term accrued interest payable. $661 thousand and $525 thousand were accrued as part of other long-term liabilities on the condensed consolidated balance sheet as of March 31, 2026 and December 31, 2025, respectively. Loan issuance costs of $174 thousand were recorded as a reduction of the principal loan balance on the condensed consolidated balance sheet and are amortized as interest expense over the term of the loan.

The outstanding long-term debt consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **March 31, <br>2026** | **December 31, <br>2025** |
| Long-term debt | $50000 | $50000 |
| Unamortized debt issuance costs | (129) | (137) |
| Total long-term debt, net | $49871 | $49863 |

---

The following table provides the components of interest expense related to the long-term debt (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Interest expense based on contractual loan rate | $1147 | $1228 |
| Amortization of debt issuance costs and accretion of final interest payment | 145 | 133 |
| Total interest expense | $1292 | $1361 |

---

The loan and security agreement provides for both affirmative and negative covenants, including covenants limiting the ability of the Company and their subsidiaries to, among other things, dispose of assets, incur debt, grant liens, pay dividends and distributions on their capital stock, make investments and acquisitions, and enter into transactions with affiliates, in each case subject to customary exceptions for a loan facility of this size and type. In addition, the loan and security agreement contains a minimum revenue covenant commencing on the earlier of the date that more than $50 million principal amount of term loans have been funded under the loan and security agreement and June 30, 2026; provided that such minimum revenue covenant shall not be tested during periods when the Company's market capitalization or unrestricted cash meet certain minimum thresholds. The occurrence of an event of default could result in the acceleration of the Company's obligations under the loan and security agreement, the termination of the lenders' commitments, a 5.0% increase in the applicable rate of interest and the exercise by the lender of other rights and remedies provided for under the loan and security agreement. The Company was in compliance with all applicable debt covenants as of March 31, 2026.

------

**Note 8. Stockholders' Equity** 

***Preferred Stock*** 

The Company is authorized to issue 10,000,000 shares of Preferred Stock.

***November 2025 Accelerated Share Repurchase Agreement***

On November 10, 2025, the Company entered into an accelerated share repurchase agreement (the ASR Agreement) with Jefferies LLC (Jefferies) to repurchase an aggregate amount of $100.0 million of its common stock. Under the ASR agreement, the Company made an aggregate upfront payment of $100.0 million to Jefferies and received an initial delivery of 1,511,553 shares of its common stock on November 12, 2025, based on the closing price of the Company's common stock on November 10, 2025. Pursuant to the terms of the ASR Agreement, Jefferies delivered 662,497 additional shares of the Company's common stock to the Company in January 2026, bringing the aggregate number of shares repurchased under the ASR Agreement to 2,174,050 shares.

Shares of common stock repurchased under the ASR Agreement are immediately retired upon receipt and returned to authorized and unissued status. Repurchased common stock is reflected as a reduction of stockholders' equity.

***July 2025 Public Offering of Common Stock***

In July 2025, the Company closed an underwritten public offering of 2,705,882 shares of its common stock at a public offering price of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $230.0 million, before deducting the underwriter discount and other offering expenses, totaling approximately $14.3 million.

***May 2024 Public Offering of Common Stock***

On May 9, 2024, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $46.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $158.7 million, before deducting the underwriter discount and other offering expenses, totaling approximately $9.7 million.

***October 2023 Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants***

On October 2, 2023, the Company closed an underwritten public offering of 3,450,000 shares of its common stock at a public offering of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other offering expenses. Concurrently, the Company also completed the closing of approximately $60.0 million for 1,825,000 shares of its common stock and 1,175,000 pre-funded warrants in a private offering pursuant to a securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99. In aggregate, the Company received $129.0 million of gross proceeds less offering costs of $8.2 million. The Company is not required under any circumstance to settle any of the pre-funded warrants for cash, and therefore classified the pre-funded warrants as permanent equity.

***December 2022 Securities Purchase Agreement***

On December 16, 2022, the Company entered into a Securities Purchase Agreement for a private placement (Private Placement) with certain entities and members of management (collectively, Purchasers). Pursuant to the Securities Purchase Agreement, the Company agreed to sell to the Purchasers warrants to purchase up to an aggregate of 22,598,870 shares of the Company's common stock, at a purchase price of $0.4425 per warrant. The closing of the Private Placement occurred on May 8, 2023 (the Issue Date), following the satisfaction of certain closing conditions, including the completion of enrollment in the randomized withdrawal period of Study C602. The Company received gross proceeds of $10.0 million for the sale and issuance of warrants to purchase common stock.

The warrants were separated into two tranches with 8,598,870 Tranche A Warrants with an exercise price of $1.75 per share and aggregate proceeds of up to approximately $15.0 million, and 14,000,000 Tranche B Warrants with an exercise price of $2.50 per share and aggregate proceeds of up to $35.0 million. The Tranche A warrants were immediately exercisable and were required to be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of Study C602. On September 26, 2023, the Company announced positive top-line data and subsequently received $15.0 million from the exercise of the Tranche A warrants. The Tranche B warrants were also immediately exercisable and, following the FDA's approval of VYKAT XR,

------

the remainder of these warrants were exercised. The Company received an aggregate of $35.0 million from the exercise of the Tranche B warrants. As of March 31, 2026, there were no remaining warrants outstanding under the Securities Purchase Agreement.

***March 2022 Public Offering of Common Stock***

On March 31, 2022, the Company sold 2,666,667 shares of its common stock at a public offering price of $3.75 per share, and for certain investors, in lieu of common stock, pre-funded warrants (the 2022 pre-funded warrants) to purchase 1,333,333 shares of its common stock at a public offering price $3.60 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.15 per share exercise price for each 2022 pre-funded warrant. The March 2022 pre-funded warrants are immediately exercisable and may be exercised at any time until all of the March 2022 pre-funded warrants are exercised in full. Each share of common stock or March 2022 pre-funded warrant was sold together with one, immediately exercisable, common warrant (the 2022 common warrants) with a five-year term to purchase one share of common stock at an exercise price of $4.50 per share. The net proceeds of the offering were $13.8 million, after deducting the underwriting discount and other offering expenses. The Company is not required under any circumstance to settle any of the 2022 pre-funded warrants or the 2022 common warrants for cash, and therefore classified both types of warrants as permanent equity.

Through March 31, 2026, 2,150,406 of the March 2022 common warrants had been exercised for gross proceeds of $9.7 million and 1,847,995 warrants were exercised using the cashless exercise option with no proceeds to the Company. As of March 31, 2026, 1,599 of the March 2022 common warrants remained outstanding.

***At the Market Offering*** 

In July 2024, the Company entered into the Sales Agreement with Jefferies, pursuant to which the Company may offer and sell up to $150.0 million of shares of its common stock, from time to time, through Jefferies.

The Company will pay Jefferies a commission of 3.0% of the aggregate gross proceeds from the sale of shares and has agreed to provide Jefferies with customary indemnification and contribution rights. The Company has also agreed to reimburse Jefferies for certain specified expenses. The Company is not obligated to sell any shares under the Sales Agreement. The offering of the shares pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement by Jefferies or the Company, as permitted therein.

***Common Stock Warrants*** 

As of March 31, 2026 and December 31, 2025, the following table summarizes the Company's outstanding common stock warrants:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **As of March 31, 2026** | **As of March 31, 2026** | **As of December 31, 2025** | **As of December 31, 2025** |  |
|  | **Number of Common Warrant Shares** | **Weighted-Average Exercise Price per Share** | **Number of Common Warrant Shares** | **Weighted-Average Exercise Price per Share** | **Expiration Date** |
| March 2022 Common warrants | 1599 | $4.50 | 1599 | $4.50 | March 2027 |
| October 2023 Pre-funded warrants | 250000 | $0.01 | 250000 | $0.01 | N/A |
| Total | 251599 |  | 251599 |  |  |

---

***Equity Incentive Plans*** 

**2014 Plan**

The Company maintains the Amended and Restated 2014 Equity Incentive Plan (the 2014 Plan). Under the 2014 Plan the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance units or performance shares to employees, directors, advisors, and consultants. Options granted under the 2014 Plan may be incentive stock options (ISOs) or nonqualified stock options (NSOs). ISOs may be granted only to Company employees, including officers and directors.

The Board has the authority to determine to whom stock options will be granted, the number of options, the term, and the exercise price. Options are to be granted at an exercise price not less than fair value. For individuals holding more than 10% of the voting rights of all classes of stock, the exercise price of an option will not be less than 110% of fair value. Performance-based grants have vesting contingent upon the achievement of certain performance criteria related to the Company's commercialization of its therapeutics. The contractual term of an option is no longer than five years for ISOs for which the grantee owns greater than 10% of the voting power of all classes of stock and no longer than ten years for all other options. The terms and conditions governing restricted stock units is at the sole discretion of the Board.

------

On February 25, 2026, the Company filed a Registration Statement on Form S-8, which registered an additional 2,091,475 shares that automatically became available for issuance under the 2014 Plan as of January 1, 2026. As of March 31, 2026, a total of 1,124,456 shares were available for future grant under the 2014 Plan.

**Inducement Plan**

The Company maintains the 2020 Inducement Equity Incentive Plan (the Inducement Plan). The Inducement Plan provides for the grant of equity-based awards, including non-statutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the 2014 Plan.

In accordance with Rule 5635(c)(4) and Rule 5635(c)(3) of the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals' bona fide period of non-employment with the Company), as an inducement material to the individuals' entry into employment with the Company, or, to the extent permitted by Rule 5635(c)(3) of the Nasdaq Listing Rules, in connection with a merger or acquisition.

As of March 31, 2026, a total of 23,068 shares were available for future grant under the Inducement Plan.

**Stock-based Compensation Expense**

The Company recognizes stock-based compensation expense related to options and restricted stock units granted to employees, directors and consultants. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive income (loss) for stock-based compensation arrangements during any of the periods presented.

Stock-based compensation expense was recognized in the condensed consolidated statements of operations and comprehensive income (loss) as follows (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Research and development | $4187 | $4314 |
| Selling, general and administrative | 11869 | 10365 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | $16056 | $14679 |

---

After the FDA approval of VYKAT XR in March 2025, the Company began capitalizing stock-based compensation associated with the allocation of labor costs related to work performed to manufacture VYKAT XR. For the three months ended March 31, 2026, the Company capitalized into inventory $0.5 million.

**Stock Options**

The Company granted options to purchase 577,525 and 587,161 shares of the Company's common stock to employees during the three months ended March 31, 2026 and 2025, respectively. The Company granted options to purchase 3,600 shares of the Company's stock to a consultant during the three months ended March 31, 2025. There were no performance-based options granted during the three months ended March 31, 2026 and 2025, respectively. The fair value of each award granted was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Expected life (years) | 6.0-6.1 | 5.9-6.1 |
| Risk-free interest rate | 3.6%-3.9% | 4.1%-4.7% |
| Volatility | 115%-117% | 118%-120% |
| Dividend rate | — % | — % |

---

The Black-Scholes option-pricing model requires the use of highly subjective assumptions to estimate the fair value of stock-based awards. These assumptions include the following estimates:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Expected life:* The expected life of stock options represents the period of time that the options are expected to be outstanding. Due to the lack of historical exercise history, the expected life of the Company's service-based stock options has been determined utilizing the "simplified method", based on the average of the contractual term of the options and the weighted-average vesting period. The expected life for the performance-based options was determined based on consideration of the contractual term of the stock options, an estimate of the date the performance criteria would be met and expectations of employee behavior.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Risk-free interest rate:* The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected life of the stock options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Volatility:* The estimated volatility rate is based on the volatilities of the Company's common stock for a historical period equal to the expected life of the stock options.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•*Dividend rate:* The Company has never declared or paid any cash dividends and does not presently plan to pay cash dividends in the foreseeable future. Consequently, the Company used an expected dividend yield of zero.

The following table summarizes stock option transactions for the three months ended March 31, 2026 under the 2014 Plan and the Inducement Plan:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of<br>Options** | **Weighted-<br>Average<br>Exercise<br>Price per** | **Weighted-<br>Average<br>Remaining<br>Contractual<br>Term** | **Aggregate Intrinsic Value** |
|  | **Outstanding** | **Share** | **(in years)** | **(in thousands)** |
| Balance at January 1, 2026 | 4032109 | $38.56 | 8.26 | $47415 |
| &nbsp;&nbsp;&nbsp;&nbsp;Options granted | 577525 | 41.95 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Options exercised | (8944) | 5.81 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Options canceled/forfeited | (87890) | 51.00 |  |  |
| Balance at March 31, 2026 | 4512800 | $38.82 | 8.18 | $27249 |
| Options exercisable at March 31, 2026 | 1819487 | $26.84 | 7.04 | $22781 |
| Options vested and expected to vest at March 31, 2026 | 4512800 | $38.82 | 8.18 | $27249 |

---

The weighted-average grant date fair value of options granted was $36.15 and $43.23 per share for the three months ended March 31, 2026 and 2025, respectively. The intrinsic value of the stock options exercised was $0.3 million and $54.8 million for the three months ended March 31, 2026 and 2025, respectively. At March 31, 2026, total unrecognized employee stock-based compensation for options that are expected to vest was $103.6 million, which is expected to be recognized over the weighted-average remaining vesting period of 3.0 years.

**Restricted Stock Units** 

There were 835,911 and 222,626 restricted stock units granted to employees by the Company during the three months ended March 31, 2026 and 2025, respectively. The shares were valued based on the Company's common stock price on the grant date.

The following table summarizes restricted stock unit transactions for the three months ended March 31, 2026 under the 2014 Plan:

---

| | | |
|:---|:---|:---|
|  | **Number of<br>Restricted Stock Units** | **Weighted-<br>Average<br>Grant-Date Fair Value per Share** |
| Outstanding at January 1, 2026 | 443291 | $56.47 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units granted | 835911 | $42.50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units vested | (84850) | $48.68 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units canceled/forfeited | (35798) | $52.68 |
| Outstanding at March 31, 2026 | 1158554 | $47.08 |

---

The weighted-average grant-date fair value of all restricted stock units granted was $42.50 and $49.17 per share during the three months ended March 31, 2026 and 2025, respectively. The fair value of all restricted stock units vested during the three months ended March 31, 2026 and 2025 was $2.7 million and $39.2 million, respectively. At March 31, 2026, total unrecognized employee stock-based compensation related to restricted stock units was $40.4 million, which is expected to be recognized over the weighted-average remaining vesting period of 2.1 years.

Certain directors have elected to delay the issuance of their vested restricted stock units granted under the 2014 Plan. A portion of these RSUs have vested as of March 31, 2026 based on the applicable service periods, but the issuance of common stock has been deferred until a future date when the directors' service to the Company terminates, or there is a change in control of the Company. The

------

grant-date fair value of these 6,500 shares is $0.3 million, which has been recognized as stock-based compensation expense over the requisite service period in the condensed consolidated statements of operations and comprehensive income (loss).

***2014 Employee Stock Purchase Plan*** 

The Company's board of directors and stockholders have adopted the 2014 Employee Stock Purchase Plan (the ESPP). The ESPP has become effective, and the board of directors will implement commencement of offers thereunder in its discretion. A total of 1,864 shares of the Company's common stock has been made available for sale under the ESPP. In addition, the ESPP provides for annual increases in the number of shares available for issuance under the plan on the first day of each year beginning in the year following the initial date that the board of directors authorizes commencement, equal to the least of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•1.0% of the outstanding shares of the Company's common stock on the first day of such year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•3,729 shares; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•such amount as determined by the board of directors.

As of March 31, 2026, there were no purchases by employees under this plan.

**Note 9. Income Taxes**

For the three months ended March 31, 2026 and 2025, the Company recorded an income tax provision of $3.5 million and zero, respectively. The Company's effective income tax rates were 9.85% and 0% for the three months ended March 31, 2026 and 2025, respectively. The increase in the effective tax rate for the three months ended March 31, 2026 is due to current taxes payable as a result of the Company being profitable for the three months ended March 31, 2026 and generating a loss for the three months ended March 31, 2025.

The Company evaluates the realizability of its deferred tax assets by assessing the valuation allowance and making adjustments to the allowance as necessary. The factors used in assessing the likelihood of realization include forecasts of future taxable income and available tax planning strategies that could be implemented. The Company's ability to achieve forecasted taxable income in the applicable taxing jurisdictions could affect the ultimate realization of its deferred tax assets. As of March 31, 2026 and December 31, 2025, the Company carried a full valuation allowance. Based on future operating results in certain jurisdictions, it is possible that the current valuation allowance positions of those jurisdictions could be adjusted during the next 12 months.

**Note 10. Net Income (Loss) per Share** 

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common stock outstanding during the period. Shares of common stock that are potentially issuable for little or no cash consideration at issuance, such as the Company's pre-funded warrants issued in October 2023, are considered outstanding common stock and are included in the calculation of basic and diluted net loss per share in connection with *ASC 260 Earnings Per Share*. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding and dilutive potential common stock that would be issued upon the exercise or vesting of common stock awards and exercise of common stock warrants that are not pre-funded using the treasury stock method which would result in the issuance of incremental shares of common stock. The Company applies the two-class method to calculate basic and diluted earnings per share as its warrants issued in March 2022 are participating securities. However, the two-class method does not impact the net loss per share of common stock as the March 2022 and May 2023 common warrants issued do not participate in losses. For the three months ended March 31, 2025, the effect of issuing potential common stock is anti-dilutive due to the net loss in the period and therefore the number of shares used to compute basic and diluted net loss per share are the same in the period.

The following securities are included in the weighted-average common shares outstanding used to calculate basic and diluted net income (loss) per common share:

------

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,** | **Three months ended March 31,** |
|  | **2026** | **2025** |
| Numerator: |  |  |
| Net income (loss) | $31378 | $(43773) |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Undistributed earnings attributable to participating securities | (1) |  |
| Net income (loss) attributable to common stockholders - basic and diluted | 31377 | (43773) |
| Denominator: |  |  |
| Common stock | 51841047 | 45928793 |
| October 2023 pre-funded warrants | 250000 | 250000 |
| Weighted-average shares - basic | 52091047 | 46178793 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock options | 824022 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units | 151902 |  |
| Weighted-average shares - diluted | 53066971 | 46178793 |
| Net income (loss) per share - basic | $0.60 | $(0.95) |
| Net income (loss) per share - diluted | $0.59 | $(0.95) |

---

The following potentially dilutive securities outstanding have been excluded from the computation of diluted net income (loss) per share because their effect would have been anti-dilutive for the periods presented:

---

| | | |
|:---|:---|:---|
|  | **Three months ended March 31,** | **Three months ended March 31,** |
|  | **2026** | **2025** |
| March 2022 common warrants | - | 516265 |
| May 2023 Tranche B warrants | - | 870628 |
| Options to purchase common stock | 3244851 | 3406719 |
| Outstanding restricted stock units | 793747 | 361991 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total | 4038598 | 5155603 |

---

**Note 11. Segment Reporting** 

The Company has one operating and reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR. The Company's chief operating decision maker (CODM) is the chief executive officer who reviews product revenue, net, and cash operating expenses on a consolidated basis to make decisions about allocating resources and assessing performance for the entire Company. The CODM does not review assets at a level or category different than the amounts disclosed in the condensed consolidated balance sheet.

The following table presents selected financial information with respect to the Company's single operating segment for the three months ended March 31, 2026 and 2025 (in thousands):

------

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Product revenue, net | $94603 | $- |
| Income (loss) before provision for income taxes | 34913 | (43773) |
| &nbsp;&nbsp;Less total other income, net | 3635 | 1970 |
| Operating income (loss) | 31278 | (45743) |
| Total operating expenses | 63325 | 45743 |
| Less non-cash expenses |  |  |
| &nbsp;&nbsp;Depreciation and amortization | (514) | (504) |
| &nbsp;&nbsp;Non-cash lease expense | (149) | (195) |
| &nbsp;&nbsp;Change in fair value of contingent consideration | (484) | (2967) |
| &nbsp;&nbsp;Stock-based compensation | (16056) | (14679) |
| Cash operating expenses | $46122 | $27398 |

---

**Note 12. Subsequent Events**

***Merger Agreement***

On April 5, 2026, the Company entered into the Merger Agreement with Neurocrine and Merger Sub, pursuant to which Neurocrine, through Merger Sub, agreed to commence the Offer to purchase all of the issued outstanding shares of the common stock of the Company, at a price per share of $53.00 per share (the Offer Price) in cash. If successful, upon the terms and conditions set forth in the Merger Agreement, the Offer will be followed by a merger of Merger Sub with and into the Company, with the Company continuing as the surviving corporation and as a direct wholly owned subsidiary of Neurocrine (the Merger).

The Offer is not subject to any financing condition. Neurocrine and Merger Sub commenced the Offer on April 20, 2026 and must keep the Offer open for 20 business days following the commencement of the Offer (determined as set forth in Rule 14d-1(g)(3) and Rule 14e-1(a) under the Securities Exchange Act of 1934, as amended), subject to possible extension under the terms of the Merger Agreement.

The Merger Agreement has been approved by the board of directors of each of Neurocrine, Merger Sub and the Company.

The foregoing description of the Offer, the Merger and the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement, which is filed as Exhibit 2.1 to the Company's Current Report on Form 8-K filed on April 6, 2026.

***Withdrawal of Marketing Authorization Application in EU***

On April 7, 2026, the Company reported that it has voluntarily withdrawn its marketing authorization application (MAA) for VIOKAT prolonged-release tablets (diazoxide choline), which is marketed in the United States as VYKAT XR. The Company had previously announced that the application has been under review by the European Medicines Agency (EMA), with a decision expected in mid-2026.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations** 

**Forward-Looking Statements**

*This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "appears," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans, or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, any projections of financial information; any statements about our continued commercialization of VYKAT XR, any statements regarding the closing of the tender offer by Neurocrine Biosciences, Inc. to purchase all of our issued and outstanding common stock, any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, our products, product sales, expenses, liquidity, cash flow, market growth rates or enforceability of our intellectual property rights and related litigation expenses; and any statements of assumptions underlying any of the foregoing. We have based these forward-looking statements on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy, and financial needs. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q. We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events, and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events, or circumstances could differ materially from those described in the forward-looking statements. All forward-looking statements are based on information and estimates available to us at the time of filing this Quarterly Report on Form 10-Q and are not guarantees of future performance. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law.*

*The interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q and this Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2025, and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K for the year ended December 31, 2025.* 

**Business Overview** 

We are a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. On March 26, 2025, we announced that our lead product candidate, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, had been approved by the U.S. Food and Drug Administration (FDA). VYKAT XR is indicated to treat hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS).

We began commercial marketing and sales and recognizing revenue during the three months ended June 30, 2025. The transaction price that we recognize as revenue for VYKAT XR sales includes an estimate of variable consideration, which includes rebates, discounts, returns, and copay assistance that are offered within our contract with our specialty pharmacy. Refer to Note 3 of the notes to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

On April 6, 2026, we announced that we had entered into an Agreement and Plan of Merger (the Merger Agreement) with Neurocrine Biosciences, Inc. (Neurocrine) and Sigma Merger Sub, Inc. (Merger Sub) on April 5, 2026, pursuant to which Neurocrine, through Merger Sub, agreed to commence a cash tender offer (the Offer) to purchase all of our issued outstanding shares of common stock at a price per share of $53.00 per share. The Offer commenced on April 20, 2026 and is expected to close during the three months ending June 30, 2026, pursuant to the terms of the Merger Agreement, with the result being that we will become a wholly-owned subsidiary of Neurocrine.

**Critical Accounting Policies and Significant Judgments and Estimates** 

Our management's discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our

------

critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

There have been no significant changes during the three months ended March 31, 2026 compared to those previously disclosed in "Critical Accounting Policies and Estimates" in "Management's Discussion and Analysis of Financial Condition and Results of Operations" included in our Annual Report on Form 10-K for the year ended December 31, 2025. Our significant accounting policies are more fully described in Note 3 of our most recent Annual Report on Form 10-K.

**Results of Operations** 

***Comparison of the three months ended March 31, 2026 and 2025 (in thousands)***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** | **Increase (decrease)** | **Increase (decrease)** |
|  | **2026** | **2025** | **Amount** | **Percentage** |
| Product revenue, net | $94603 | $- | $94603 | 100% |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | 1198 | - | 1198 | 100% |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 11274 | 13517 | (2243) | (17%) |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 50369 | 29259 | 21110 | 72% |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | 484 | 2967 | (2483) | (84%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 63325 | 45743 | 17582 | 38% |
| Operating income (loss) | 31278 | (45743) | 77021 | (168%) |
| Other income (expense), net |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 4927 | 3331 | 1596 | 48% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1292) | (1361) | 69 | (5%) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense), net | 3635 | 1970 | 1665 | 85% |
| Income (loss) before provision for income taxes | 34913 | (43773) | 78686 | (180%) |
| Provision for income taxes | 3535 | - | 3535 | 100% |
| Net income (loss) | $31378 | $(43773) | $75151 | (172%) |

---

***Product revenue, net***

Product revenue, net was $94.6 million for the three months ended March 31, 2026, due to sales of VYKAT XR after FDA approval was obtained in March 2025, compared to zero for the three months ended March 31, 2025.

***Cost of goods sold***

Cost of goods sold was $1.2 million for the three months ended March 31, 2026, due to sales of VYKAT XR after FDA approval was obtained in March 2025, compared to zero for the three months ended March 31, 2025. Prior to receiving FDA approval, costs associated with the manufacturing of VYKAT XR were expensed as research and development expense. As such, a portion of the cost of inventory sold during the period was expensed prior to FDA approval.

***Research and development expense*** 

Research and development expenses were $11.3 million for the three months ended March 31, 2026, a decrease of $2.2 million from the three months ended March 31, 2025. Pre-commercial launch and development costs, 2025 MAA submission in Europe, supply chain activities, and clinical activities decreased $2.2 million between comparable periods. The cadence of our research and development expenditures will fluctuate depending upon the state of our clinical programs, the timing of manufacturing and other projects necessary to support the submission of our regulatory filings and research activities.

***Selling, general and administrative expense*** 

Selling, general and administrative expenses were $50.4 million for the three months ended March 31, 2026, an increase of $21.1 million from the three months ended March 31, 2025. Personnel costs including hiring expense and other associated headcount costs increased $12.7 million as we have hired additional employees in support of our commercial launch and increased business activities. New program costs associated with commercial launch activities, including disease state education, analytics, other

------

marketing programs, medical affairs and patient advocacy activities increased $7.1 million and costs for international expansion increased $1.2 million. Selling, general and administrative expenses are anticipated to increase as we continue commercialization of VYKAT XR.

***Change in fair value of contingent consideration***

We are obligated to make cash payments up to a maximum of $20.9 million to the former Essentialis stockholders upon the achievement of certain commercial milestones associated with the sales of VYKAT XR in accordance with the terms of our 2017 merger agreement with Essentialis. We achieved the first commercial milestone of $100 million in cumulative revenue in our fourth quarter 2025 and subsequently paid $4.0 million during the three months ended March 31, 2026 and recorded $2.9 million for the remainder in accounts payable. We achieved the second and final commercial milestone of $200 million in cumulative revenue in our first quarter 2026. The fair value of the second and final payment was $13.8 million as of March 31, 2026. During the three months ended March 31, 2025, the fair value increased by $3.0 million from the $14.8 million fair value as of December 31, 2024.

***Other income (expense), net***

We had other income (expense), net of $3.6 million in the three months ended March 31, 2026, compared to $2.0 million during the three months ended March 31, 2025. The increase was primarily due to an increase in interest income driven by higher cash and cash equivalents and marketable securities.

**Liquidity and Capital Resources** 

We had net income of $31.4 million, generated $26.0 million of net cash from operating activities during the three months ended March 31, 2026 and had an accumulated deficit of $400.0 million at March 31, 2026 as a result of losses incurred prior to 2025. We had $133.0 million in cash and cash equivalents, $396.0 million of marketable securities and $268.3 million of working capital on March 31, 2026. We had lease obligations totaling $4.4 million to be paid through August 2029, consisting of two operating leases for office space in Redwood City, California.

As of March 31, 2026, we had $50.0 million outstanding under our loan and security agreement with Oxford. Under the terms of the loan agreement with Oxford, following FDA approval of VYKAT XR, an additional $50 million became available through September 30, 2025, but was not drawn down. Following the amendment of our loan and security agreement in November 2025, the final three tranches of an aggregate of $100 million may be made available upon mutual consent with Oxford. As a result of a milestone achieved in 2025, the loan carries an interest-only period of 60 months and a total term of 72 months. The term loan accrues interest at a floating rate equal to, subject to certain conditions, (a) 1-month term SOFR plus (b) 5.50%.

In July 2025, we closed an underwritten public offering of 2,705,882 shares of our common stock at a public offering price of $85.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares of our common stock. The gross proceeds of the public offering were $230.0 million, before deducting the underwriter discount and other offering expenses, totaling approximately $14.3 million.

We believe that our existing cash, cash equivalents and marketable securities and cash flows from operations will be sufficient to meet the company's working capital needs for the next twelve months. Our long-term capital requirements will depend on several factors, most notably the timing and degree of success of our continued commercialization of VYKAT XR. We believe that we will continue to have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means, but the access to such capital resources is uncertain and is not assured.

**Cash Flows** 

The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net cash provided by (used in) operating activities | $25980 | $(32752) |
| Net cash provided by investing activities | 37983 | 22937 |
| Net cash provided by (used in) financing activities | (1043) | 3218 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents | $62920 | $(6597) |

---

------

***Net cash provided by (used in) operating activities*** 

During the three months ended March 31, 2026, operating activities provided net cash of $26.0 million, which was primarily due to net income of $31.4 million which included $16.1 million of stock-based compensation, $0.5 million of depreciation and amortization, $0.1 million of non-cash lease expense, non-cash expense of $0.5 million for the change in fair value of contingent consideration, and $0.2 million added back for accretion of premium/discount on marketable securities. Additionally, there was a $22.4 million net increase in cash used during the three months ended March 31, 2026 due to changes in operating assets and liabilities.

During the three months ended March 31, 2025, operating activities used net cash of $32.8 million, which was primarily due to net loss of $43.8 million which included $14.7 million of stock-based compensation, $0.5 million of depreciation and amortization, $0.2 million of non-cash lease expense, non-cash expense of $3.0 million for the change in fair value of contingent consideration, and $1.0 million added back for accretion of premium/discount on marketable securities. Additionally, there was a $6.4 million net increase in cash used during the three months ended March 31, 2025 due to changes in operating assets and liabilities.

***Net cash provided by investing activities*** 

During the three months ended March 31, 2026, we used $101.3 million for purchases of marketable securities. We received proceeds of $139.3 million from maturities of marketable securities.

During the three months ended March 31, 2025, we used $45.4 million for purchases of marketable securities. We received proceeds of $68.3 million from maturities of marketable securities.

***Net cash provided by (used in) financing activities*** 

During the three months ended March 31, 2026, we paid $1.1 million in milestone payments equal to the amount of contingent consideration liability recognized at the Essentialis acquisition date related to achieving the first commercial milestone partially offset by $0.1 million of proceeds from the exercise of stock options.

During the three months ended March 31, 2025, we received $3.0 million from the exercise of common stock warrants. We also received $0.3 million from the exercise of stock options. We paid $0.1 million of debt issuance costs.

**Off-Balance Sheet Arrangements** 

As of March 31, 2026 and December 31, 2025, we had no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.

**Recent Accounting Pronouncements**

See "Recent Accounting Pronouncements" described in Note 3, Basis of Presentation and Summary of Significant Accounting Policies within Notes to the Condensed Consolidated Financial Statements.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk** 

There have not been any material changes to our exposure to market risk during the three months ended March 31, 2026. For additional information regarding market risk, refer to Part II, Item *7A Qualitative and Quantitative Disclosures About Market Risk* in our Annual Report on Form 10-K for the year ended December 31, 2025.

**Item 4. Controls and Procedures** 

***Inherent Limitations on Effectiveness of Controls*** 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, even if determined effective and no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives to prevent or detect misstatements. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Evaluation of Disclosure Controls and Procedures** 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (Exchange Act), is recorded, processed, summarized and reported within the time periods specified in U.S. Securities and Exchange Commission, or SEC, rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls were effective at the reasonable assurance level.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Changes in Internal Control over Financial Reporting** 

There have been no changes to our internal control over financial reporting that occurred during the three months ended March 31, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**PART II – OTHER INFORMATION** 

**Item 1. Legal Proceedings** 

We may, from time to time, be party to litigation and subject to claims that arise in the ordinary course of business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We currently believe that these ordinary course matters will not have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

On March 6, 2026, the City of Pontiac Police and Fire Retirement System, a purported stockholder, filed a class-action complaint for violations of the Federal securities laws (the Complaint) against us and the members of our management (collectively, Defendants) in the United States District Court for the Northern District of California. See City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc. et. al., Case No. 3:26-cv-01979 (N.D. Cal.). The plaintiff alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 on behalf of a putative class of purchasers of the Company's common stock during a purported class period of March 26, 2025 through November 4, 2025. We believe we have meritorious defenses and will vigorously defend this and any other similarly-based litigation should it arise. We cannot provide any assurance as to the possible outcome or cost to us from this action, particularly as it is at an early stage, nor how long it may take to resolve.

**Item 1A. Risk Factors** 

An investment in our securities has a high degree of risk. Before you invest, you should carefully consider the risks and uncertainties. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial conditions and/or operating results. If any of these risks actually occur, our business, operating results and financial condition could be harmed, and the value of our stock could go down. This means you could lose all or a part of your investment. We have included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025, a description of certain risks and uncertainties that could affect our business, future performance or financial condition (the Risk Factors). There have been no material changes from the disclosure provided in the Form 10-K with respect to the Risk Factors other than as set forth below.

***The pendency of the tender offer for our common stock could have an adverse effect on our business and the failure to complete the tender offer in a timely manner or at all could adversely affect our business, financial condition, results of operations and stock price.***

On April 5, 2026, we entered into an Agreement and Plan of Merger (the Merger Agreement) with Neurocrine Biosciences, Inc. (Neurocrine) and Sigma Merger Sub, Inc. (Merger Sub), pursuant to which Neurocrine, through Merger Sub, agreed to commence a tender offer to purchase all of the issued and outstanding shares of our common stock at a price per share of $53.00 per share (the Offer). The Offer commenced on April 20, 2026 and is expected to close during the three months ending June 30, 2026, pursuant to the terms of the Merger Agreement, with the result being that the Company will become a wholly-owned subsidiary of Neurocrine (the Merger).

The Offer may be delayed, and may ultimately not be completed, due to a number of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•there are uncertainties as to the timing of the Offer and transactions contemplated by the Merger Agreement, including the risk that the Offer or subsequent Merger may not be completed in a timely manner or at all;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the Offer is subject to certain closing conditions that could adversely affect us or cause the transaction to be abandoned; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the occurrence of certain events, changes or other circumstances could give rise to the termination of the Merger Agreement.

If the Offer does not close, we may suffer other consequences that could adversely affect our business, financial condition, results of operations, and stock price, and our stockholders would be exposed to additional risks, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•to the extent the current market price of our stock reflects an assumption that the Offer will be completed, the market price of our common stock could decrease if the Offer is not completed;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•investor confidence in us could decline, stockholder litigation could be brought against us, relationships with existing and prospective service providers, investors, lenders and other business partners may be adversely impacted, we may be unable to retain key personnel, and our operating results may be adversely impacted due to costs incurred in connection with the Offer;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the risks related to the diversion of attention of our management or employees, the uncertainty our employees may have about their roles upon consummation of the Offer, and the ability for us to attract and retain key talent, including senior leaders, to the same extent that we have previously been able to attract and retain employees during the pendency of the Offer; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the requirement that we pay Neurocrine a termination fee under certain circumstances that give rise to the termination of the Merger Agreement.

There can be no assurance that our business, relationships with other parties, liquidity or our financial condition will not be adversely affected, as compared to the condition prior to the announcement of the Offer, if the Offer is not consummated. Even if successfully completed, there are certain risks to our stockholders from the Offer, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•we may experience a departure of employees, prior to the closing of the Offer; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•if the Offer is completed, our stockholders will forego the opportunity to realize the potential long-term value of the successful execution of our current strategy as an independent company.

***While the Offer is pending, we are subject to business uncertainties and contractual restrictions that could harm our business relationships, financial condition, results of operations and business.***

During the period prior to the closing of the Offer and pursuant to the terms of the Merger Agreement, our business is exposed to certain inherent risks and contractual restrictions that could harm our business relationships, financial condition, results of operations and business, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the possibility of disruption to our business and operations resulting from the announcement and pendency of the Offer, including diversion of management attention and resources;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the inability to attract and retain key personnel and recruit prospective employees, and the possibility that our current employees could be distracted, and their productivity decline as a result, due to uncertainty regarding the Offer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the inability to pursue alternative business opportunities or make changes to our business pending the completion of the Offer, and other restrictions on our ability to conduct our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our inability to solicit other acquisition proposals during the pendency of the Offer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the amount of the costs, fees, expenses, and charges related to the Merger Agreement and the Merger, including but not limited to the cost of professional services, insurance, and any legal proceeding that may be instituted against us, which may materially and adversely affect our financial condition; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•other developments beyond our control, including, but not limited to, changes in domestic or global economic conditions that may affect the timing or success of the Merger.

If any of these effects were to occur, it could adversely impact our business, cash flow, results of operations or financial condition, as well as the market price of our common stock and our perceived value, regardless of whether the Offer is completed.

***Our international expansion plans in the European Union have been delayed.*** 

On April 7, 2026, we reported that we had voluntarily withdrawn our marketing authorization application (MAA) for VIOKAT prolonged-release tablets (diazoxide choline), which is marketed in the United States as VYKAT<sup>TM</sup> XR. We had previously announced that the application had been under review by the European Medicines Agency (EMA), with a decision expected in mid-2026. The withdrawal of the MAA will delay any commercialization plans for our products in the EU, which may have an adverse effect on our financial condition, cash flows and results of operations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds** 

None.

**Item 3. Defaults Upon Senior Securities** 

None.

**Item 4. Mine Safety Disclosures** 

Not applicable.

------

**Item 5. Other Information** 

We have social media posts at X (formerly Twitter) - @SolenoTX and LinkedIn - Soleno Therapeutics, Inc. It is possible that information we post on social media channels could be deemed to be material information. The information on, or that may be accessed through, our website and social media channels is not incorporated by reference into this Quarterly Report on Form 10-Q and should not be considered a part of this Quarterly Report on Form 10-Q.

**(c) *Insider Adoption or Termination of Trading Arrangements***

During the three months ended March 31, 2026, the Company did not adopt, modify or terminate and no directors or officers, as defined in Rule 16a-1(f), adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Regulation S-K Item 408.

**Item 6. Exhibits** 

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report on Form 10-Q, which Exhibit Index is incorporated herein by reference.

------

**EXHIBIT INDEX**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference from** | **Incorporated by Reference from** | **Incorporated by Reference from** | **Incorporated by Reference from** |
| **Exhibit**<br>**Number** | **Description of Document** | **Registrant's**<br>**Form** | **Date Filed**<br>**with the SEC** | **Exhibit**<br>**Number** | **Filed**<br>**Herewith** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.1 | &nbsp;&nbsp;[<u>Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended</u>](slno-ex31_1.htm) |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31.2 | &nbsp;&nbsp;[<u>Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934, as amended</u>](slno-ex31_2.htm) |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32.1† | &nbsp;&nbsp;[<u>Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. §1350</u>](slno-ex32_1.htm) |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32.2† | &nbsp;&nbsp;[<u>Certification of Principal Financial and Accounting Officer Required Under Rule 13a-14(b) of the Securities and Exchange Act of 1934, as amended, and 18 U.S.C. §1350</u>](slno-ex32_2.htm) |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;101.INS | &nbsp;&nbsp;Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;101.SCH | &nbsp;&nbsp;Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents. |  |  |  | X |
| &nbsp;&nbsp;&nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page formatted as Inline XBRL and contained in Exhibit 101.<br>|  |  |  | X |

---

† The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: May 7, 2026 | **SOLENO THERAPEUTICS, INC.** | **SOLENO THERAPEUTICS, INC.** |
|  | By: | /s/ Jennifer Fulk |
|  |  | Jennifer Fulk<br>Chief Financial Officer<br>**(authorized officer and principal financial and <br>accounting officer)** |

---

------

## Exhibit 31.1

**Exhibit 31.1** 

**CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER** 

**PURSUANT TO** 

**SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)** 

I, Anish Bhatnagar, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ Anish Bhatnagar |
| Anish Bhatnagar |
| President, Chief Executive Officer |
| (principal executive officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2** 

**CERTIFICATION OF THE CHIEF FINANCIAL OFFICER** 

**PURSUANT TO** 

**SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)** 

I, Jennifer Fulk, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Soleno Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 7, 2026

---

| |
|:---|
| /s/ Jennifer Fulk |
| Jennifer Fulk |
| Chief Financial Officer |
| (principal financial and accounting officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1** 

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the "Company") on Form 10-Q for the fiscal quarter ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), Anish Bhatnagar, President, Chief Executive Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2026

---

| |
|:---|
| /s/ Anish Bhatnagar |
| Anish Bhatnagar |
| President, Chief Executive Officer |
| (principal executive officer) |

---

------

## Exhibit 32.2

**Exhibit 32.2** 

**CERTIFICATION PURSUANT TO** 

**18 U.S.C. SECTION 1350,** 

**AS ADOPTED PURSUANT TO** 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002** 

In connection with the Quarterly Report of Soleno Therapeutics, Inc. (the "Company") on Form 10-Q for the fiscal quarter ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), Jennifer Fulk, Chief Financial Officer of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2026

---

| |
|:---|
| /s/ Jennifer Fulk |
| Jennifer Fulk |
| Chief Financial Officer |
| (principal financial and accounting officer) |

---

------